<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35489767</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1791-7530</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>42</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Anticancer research</Title>
          <ISOAbbreviation>Anticancer Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Circulating Tumor Cells Derived from Advanced Hepatocellular Carcinoma Rapidly Develop Resistance to Cytotoxic Chemotherapy.</ArticleTitle>
        <Pagination>
          <StartPage>2479</StartPage>
          <EndPage>2486</EndPage>
          <MedlinePgn>2479-2486</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.21873/anticanres.15726</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND/AIM" NlmCategory="OBJECTIVE">Clinically, some cancer patients develop drug resistance after receiving a few courses of chemotherapy, or even worse, completely lack therapeutic response. Prediction of treatment response before administration is of value to oncologists. This study aimed to evaluate the feasibility of drug sensitivity tests for circulating tumor cells (CTCs) isolated from patients with advanced hepatocellular carcinoma (HCC).</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">CTCs isolated from patients receiving cytotoxic chemotherapy or sorafenib were subjected to drug tests using ex vivo culture. Thirty-one patients with advanced HCC and one with benign lesions were enrolled in the study.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">After incubation with chemotherapeutic drugs ex vivo, the numbers of CTCs were decreased in 10/12 (83.3%) of treatment-naïve patients (planning to receive the first course of chemotherapy) but increased in all patients (6/6) who had received chemotherapy (p=0.002). The CTC count was negatively correlated with the overall survival of patients (p=0.016). The CTCs of patients who received targeted therapy (n=11), were incubated with sorafenib for sensitivity tests. After comparing the chemotherapy and sorafenib-treated groups, the CTCs in the latter group had a lower probability to develop drug resistance (p=0.031).</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">An ex vivo culture-based drug sensitivity test was developed for CTCs isolated from advanced HCC patients. The drug test found that resistance developed rapidly following cytotoxic chemotherapy, whereas it was rarely observed in patients receiving sorafenib. For patients with advanced HCC who choose to receive chemotherapy, CTC drug sensitivity tests may help predict treatment response.</AbstractText>
          <CopyrightInformation>Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Hsieh</LastName>
            <ForeName>Chia-Hsun</ForeName>
            <Initials>CH</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital Linkou Main Branch, Taoyuan, Taiwan, R.O.C.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yeh</LastName>
            <ForeName>Chau-Ting</ForeName>
            <Initials>CT</Initials>
            <AffiliationInfo>
              <Affiliation>Liver Research Center, Chang Gung Memorial Hospital Linkou Main Branch, Taoyuan, Taiwan, R.O.C.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Molecular Medicine Research Center, Chang Gung University, Taoyuan, Taiwan, R.O.C.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Ya-Hui</ForeName>
            <Initials>YH</Initials>
            <AffiliationInfo>
              <Affiliation>Liver Research Center, Chang Gung Memorial Hospital Linkou Main Branch, Taoyuan, Taiwan, R.O.C.; e1249060@gmail.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Molecular Medicine Research Center, Chang Gung University, Taoyuan, Taiwan, R.O.C.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lai</LastName>
            <ForeName>Ming-Wei</ForeName>
            <Initials>MW</Initials>
            <AffiliationInfo>
              <Affiliation>Liver Research Center, Chang Gung Memorial Hospital Linkou Main Branch, Taoyuan, Taiwan, R.O.C.; a22141@cgmh.org.tw.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Molecular Medicine Research Center, Chang Gung University, Taoyuan, Taiwan, R.O.C.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Pediatric Gastroenterology, Department of Pediatrics, Chang Gung Memorial Hospital Linkou Main Branch, Taoyuan, Taiwan, R.O.C.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Greece</Country>
        <MedlineTA>Anticancer Res</MedlineTA>
        <NlmUniqueID>8102988</NlmUniqueID>
        <ISSNLinking>0250-7005</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>9ZOQ3TZI87</RegistryNumber>
          <NameOfSubstance UI="D000077157">Sorafenib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006528" MajorTopicYN="Y">Carcinoma, Hepatocellular</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008113" MajorTopicYN="Y">Liver Neoplasms</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009360" MajorTopicYN="Y">Neoplastic Cells, Circulating</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077157" MajorTopicYN="N">Sorafenib</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Circulating tumor cells</Keyword>
        <Keyword MajorTopicYN="N">chemotherapy</Keyword>
        <Keyword MajorTopicYN="N">drug resistance</Keyword>
        <Keyword MajorTopicYN="N">ex vivo culture</Keyword>
        <Keyword MajorTopicYN="N">sorafenib</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>30</Day>
          <Hour>20</Hour>
          <Minute>43</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35489767</ArticleId>
        <ArticleId IdType="doi">10.21873/anticanres.15726</ArticleId>
        <ArticleId IdType="pii">42/5/2479</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
